144 related articles for article (PubMed ID: 35318257)
41. Angiomatoid features in fibrohistiocytic sarcomas. Immunohistochemical, ultrastructural, and clinical distinction from vascular neoplasms.
Costa MJ; McGlothlen L; Pierce M; Munn R; Vogt PJ
Arch Pathol Lab Med; 1995 Nov; 119(11):1065-71. PubMed ID: 7487409
[TBL] [Abstract][Full Text] [Related]
42. A study of CD117 expression in dermatofibrosarcoma protuberans and cellular dermatofibroma.
Labonte S; Hanna W; Bandarchi-Chamkhaleh B
J Cutan Pathol; 2007 Nov; 34(11):857-60. PubMed ID: 17944726
[TBL] [Abstract][Full Text] [Related]
43. Immunohistochemical characterization of dermatofibrosarcoma protuberans with practical applications for diagnosis and treatment.
Haycox CL; Odland PB; Olbricht SM; Piepkorn M
J Am Acad Dermatol; 1997 Sep; 37(3 Pt 1):438-44. PubMed ID: 9308560
[TBL] [Abstract][Full Text] [Related]
44. Mast cells in cutaneous tumors: innocent bystander or maestro conductor?
Biswas A; Richards JE; Massaro J; Mahalingam M
Int J Dermatol; 2014 Jul; 53(7):806-11. PubMed ID: 23621615
[TBL] [Abstract][Full Text] [Related]
45. Immunohistochemical expression of matrix metalloproteinases 1, 2, 9, and 14 in dermatofibrosarcoma protuberans and common fibrous histiocytoma (dermatofibroma).
Weinrach DM; Wang KL; Wiley EL; Laskin WB
Arch Pathol Lab Med; 2004 Oct; 128(10):1136-41. PubMed ID: 15387709
[TBL] [Abstract][Full Text] [Related]
46. Recent advances in the diagnosis, classification and molecular pathogenesis of cutaneous mesenchymal neoplasms.
Papke DJ; Hornick JL
Histopathology; 2022 Jan; 80(1):216-232. PubMed ID: 34958499
[TBL] [Abstract][Full Text] [Related]
47. Fat necrosis with an associated lymphocytic infiltrate represents a histopathologic clue that distinguishes cellular dermatofibroma from dermatofibrosarcoma protuberans.
Schechter SA; Bresler SC; Patel RM
J Cutan Pathol; 2020 Oct; 47(10):913-916. PubMed ID: 32412128
[TBL] [Abstract][Full Text] [Related]
48. Tenascin expression in cutaneous fibrohistiocytic tumors. Immunohistochemical investigation of 24 cases.
Franchi A; Santucci M
Am J Dermatopathol; 1996 Oct; 18(5):454-9. PubMed ID: 8902090
[TBL] [Abstract][Full Text] [Related]
49. Cutaneous mesenchymal tumours: an update.
Mentzel T
Pathology; 2014 Feb; 46(2):149-59. PubMed ID: 24378387
[TBL] [Abstract][Full Text] [Related]
50. CD34 and factor XIIIa in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans.
Abenoza P; Lillemoe T
Am J Dermatopathol; 1993 Oct; 15(5):429-34. PubMed ID: 7694515
[TBL] [Abstract][Full Text] [Related]
51. Haemorrhagic dermatomyofibroma (plaque-like dermal fibromatosis): clinicopathological and immunohistochemical analysis of three cases resembling plaque-stage Kaposi's sarcoma.
Mentzel T; Kutzner H
Histopathology; 2003 Jun; 42(6):594-8. PubMed ID: 12786896
[TBL] [Abstract][Full Text] [Related]
52. Evaluation of CD10 and procollagen 1 expression in atypical fibroxanthoma and dermatofibroma.
de Feraudy S; Mar N; McCalmont TH
Am J Surg Pathol; 2008 Aug; 32(8):1111-22. PubMed ID: 18545147
[TBL] [Abstract][Full Text] [Related]
53. Flow-cytometric DNA analysis in cutaneous fibrohistiocytic tumors.
Okita H; Ohtsuka T; Yamazaki S
Dermatology; 2003; 207(4):357-61. PubMed ID: 14657626
[TBL] [Abstract][Full Text] [Related]
54. Could cathepsin-k be a driver of the myofibroblastic differentiation observed in dermatofibroma, atypical fibroxanthoma and pleomorphic dermal sarcoma?
Ricci C; De Leo A; Dika E; Lambertini M; Veronesi G; Corti B
Acta Histochem; 2020 Feb; 122(2):151498. PubMed ID: 31889532
[TBL] [Abstract][Full Text] [Related]
55. Deep "benign" fibrous histiocytoma: clinicopathologic analysis of 69 cases of a rare tumor indicating occasional metastatic potential.
Gleason BC; Fletcher CD
Am J Surg Pathol; 2008 Mar; 32(3):354-62. PubMed ID: 18300816
[TBL] [Abstract][Full Text] [Related]
56. ALK rearrangement and overexpression in epithelioid fibrous histiocytoma.
Doyle LA; Mariño-Enriquez A; Fletcher CD; Hornick JL
Mod Pathol; 2015 Jul; 28(7):904-12. PubMed ID: 25857825
[TBL] [Abstract][Full Text] [Related]
57. Dermatofibroma Versus Dermatofibrosarcoma Protuberans: A Nuclear Morphology Study.
Khamdan F; Brailsford C; Dirr MA; Sagut P; Nietert PJ; Elston D
Am J Dermatopathol; 2023 Sep; 45(9):631-634. PubMed ID: 37625803
[TBL] [Abstract][Full Text] [Related]
58. The expression levels of thrombospondin-1 in dermatofibroma and dermatofibrosarcoma protuberans.
Maekawa T; Jinnin M; Ohtsuki M; Ihn H
Eur J Dermatol; 2011; 21(4):534-8. PubMed ID: 21697041
[TBL] [Abstract][Full Text] [Related]
59. Expression of MMP-2, MMP-9 and MMP-11 in dermatofibroma and dermatofibrosarcoma protuberans.
Chen YT; Chen WT; Huang WT; Wu CC; Chai CY
Kaohsiung J Med Sci; 2012 Oct; 28(10):545-9. PubMed ID: 23089320
[TBL] [Abstract][Full Text] [Related]
60. TLE1 expression fails to distinguish between synovial sarcoma, atypical fibroxanthoma, and dermatofibrosarcoma protuberans.
Pukhalskaya T; Smoller BR
J Cutan Pathol; 2020 Feb; 47(2):135-138. PubMed ID: 31614009
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
